Ethyl (R)-(-)-4-cyano-3-hydroxybutyate

We are Ethyl (R)-(-)-4-cyano-3-hydroxybutyate CAS:141942-85-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Ethyl (R)-(-)-4-cyano-3-hydroxybutyate
CAS.NO:141942-85-0
Synonyms:Ethyl (R)-(-)-4-cyano-3-hydroxybutyate
Ethyl (R)-(−)-4-cyano-3-hydroxybutyrate
(R)-(-)-4-Cyano-3-hydroxybutyratic acid,ethyl ester
(R)-(-)-4-Cyano-3-hydroxybutyric Acid Ethyl Ester
Ethyl (R)-(-)-4-cyano-3-hydroxybutyrate
Ethyl (R)-4-cyano-3-hydroxybutanoate
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 325.6±27.0 °C at 760 mmHg
Molecular Formula C7H11NO3
Molecular Weight 157.167
Flash Point 150.7±23.7 °C
 
Specification:
Appearance:Colorless to light yellow transparent liquid
Assay:≥98.0%
Refractive index:1.4450-1.4500
Specific rotation:-29~-34°
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Atorvastatin(CAS:110862-48-1) and Atorvastatin calcium(CAS:134523-03-8).

Ethyl (R)-(-)-4-cyano-3-hydroxybutyate


Related News: The risk-based score generated by the tool helps sponsors gain advance understanding of the appropriate level of clinical supply management oversight needed to help get their project started on time and maintain momentum as the study progresses.methyl (E)-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate CAS:1168150-46-6 It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad.Triethylsilane CAS:617-86-7 Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.5471-51-2 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said.

Related Products
Product Name
L-Norvaline View Details
2,5-DICHLOROFLUOROBENZENE View Details
2-[2-(4-chlorophenoxy)phenyl]acetic acid View Details
Trichloro(1H,1H,2H,2H-tridecafluoro-n-octyl)silane manufacturer (4-pyren-1-ylphenyl)boronic acid manufacturer [2-Oxo-3-[3-(trifluoromethyl)phenoxy]propyl]phosphonic Acid Dimethyl Ester manufacturer 2-(chloromethyl)-1,3-dioxolane manufacturer D-Homophenylalanine manufacturer